<DOC>
	<DOCNO>NCT00410787</DOCNO>
	<brief_summary>The primary purpose study characterize pain control achieve long-term repeated dose OROS hydromorphone ( slow release ) patient chronic cancer pain secondary purpose characterize effect pain patient ' quality life long-term , repeat dose OROS hydromorphone ( slow release ) take patient chronic cancer pain .</brief_summary>
	<brief_title>Safety Tolerability Long-term Administration OROS Hydromorphone HCI ( Slow Release ) Cancer Pain</brief_title>
	<detailed_description>Study DO-118X phase-3 , multicenter , open-label extension study adult patient cancer pain successfully complete Study DO-118 dose-stable pain control take least 8 mg OROS hydromorphone ( slow release ) equivalent morphine sulfate SR ( slow release ) dosage . Patients start dose OROS hydromorphone equivalent opioid dose achieve dose-stable pain control SR ( slow release ) phase Study DO-118 . Patients return study clinic month 1 year . Dosage adjustment study medication breakthrough pain medication permit . OROS hydromorphone HCI ( slow release ) tablets 8 , 16 , 32 64mg dos administer orally every 24 hour</detailed_description>
	<mesh_term>Hydromorphone</mesh_term>
	<criteria>Patients chronic cancer pain , successfully complete OROS hydromorphone SR ( slow release ) study , DO118 Patients must dosestable pain control last two day slow release phase study Patients require least 8mg OROS hydromorphone slow release every 24 hour management chronic cancer pain Pain consider potentially responsive opioids Gastrointestinal disease sufficient severity likely interfere oral analgesia include : dysphagia , vomit , bowel movement bowel obstruction due impaction within 5 day prior start trial , severe gut narrowing may affect absorption transit orally administer drug , particularly insoluble OROS outer coat Any patient risk treatment hydromorphone outweigh potential benefit . Such risk category include : raise intracranial pressure , hypotension , hypothyroidism , asthma , reduce respiratory reserve , prostatic hypertrophy , hepatic impairment , renal impairment , elderly debilitate , convulsive disorder Addison 's disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Chronic cancer pain</keyword>
	<keyword>OROS hydromorphone HCI ( slow release )</keyword>
	<keyword>long-term repeat dose</keyword>
</DOC>